Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Lung Cancer

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2009.04.002PMID 19477032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.

  2009cited by this paper
• Molecular predictive factors for progression of high-grade preinvasive bronchial lesions.

  2008cited by this paper
• Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage.

  2008cited by this paper
• In vivo Optical Coherence Tomography Imaging of Preinvasive Bronchial Lesions

  2008cited by this paper
• High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.

  2008cited by this paper
• Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

  2007cited by this paper
• Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy.

  2007cited by this paper
• 薬剤排出トランスポーター蛋白（Breast Cancer Resistance Protein, BCRP）の発現と光線力学的治療（PDT）の抗腫瘍効果との関係

  2007cited by this paper
• The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

  2007cited by this paper
• Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program

  2007cited by this paper
• Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

  2007cited by this paper
• Role of pharmacogenetics in irinotecan therapy.

  2006cited by this paper
• Photodynamic therapy and anti‐tumor immunity

  2006cited by this paper
• Early detection of bronchial lesions using newly developed videoendoscopy-based autofluorescence bronchoscopy.

  2006cited by this paper
• PDT‐associated host response and its role in the therapy outcome

  2006cited by this paper
• Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment

  2006cited by this paper
• Photodynamic therapy (PDT) for lung cancers.

  2006cited by this paper
• Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.

  2006cited by this paper
• Basic and clinical research on photodynamic therapy at Tokyo Medical University Hospital

  2006influential reference
• EXPRESSION AND FUNCTION OF ABCB1 AND ABCG2 IN HUMAN PLACENTAL TISSUE

  2005cited by this paper
• Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.

  2005cited by this paper
• Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics

  2005cited by this paper
• ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy

  2005cited by this paper
• The natural course of preneoplastic lesions in bronchial epithelium.

  2005cited by this paper
• Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

  2004cited by this paper
• Gefitinib reverses breast cancer resistance protein-mediated drug resistance.

  2004cited by this paper
• Association Between the Photodynamic Loss of Bcl-2 and the Sensitivity to Apoptosis Caused by Phthalocyanine Photodynamic Therapy¶

  2003cited by this paper
• Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.

  2003cited by this paper
• Domain-dependent Photodamage to Bcl-2

  2003cited by this paper
• Molecular markers of outcome after radiotherapy in patients with prostate carcinoma

  2003cited by this paper
• An Update on Photodynamic Therapy Applications

  2002cited by this paper
• Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material

  2002cited by this paper
• The role of apoptosis in response to photodynamic therapy: what, where, why, and how

  2002cited by this paper
• The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

  2002cited by this paper
• Increased cytotoxic effects of photodynamic therapy in IL‐6 gene transfected cells via enhanced apoptosis

  2001cited by this paper
• Photodynamic therapy-induced death of MCF-7 human breast cancer cells: a role for caspase-3 in the late steps of apoptosis but not for the critical lethal event.

  2001cited by this paper
• Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.

  2000cited by this paper
• PHOTODYNAMIC THERAPY FOR LUNG CANCER

  1999cited by this paper
• Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate.

  1998cited by this paper
• Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

  1995cited by this paper
• p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.

  1994cited by this paper
• Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.

  1991cited by this paper
• Photodynamic Therapy

  1988cited by this paper

• Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma

  2025cites this paper
• Advances in Photodynamic Therapy for Central-type Lung Cancer: Clinical Outcomes and Adverse Events

  2024cites this paper
• Recent advances in BCRP‐induced breast cancer resistance treatment with marine‐based natural products

  2023cites this paper
• Toward a Better Understanding of NRF2/NFE2L2 and BCRP/ABCG2 in Therapy Resistance in Cancer

  2023cites this paper
• In Vitro Comparative Study of Near-Infrared Photoimmunotherapy and Photodynamic Therapy

  2023cites this paper
• Multifunctional Nanoplatforms as a Novel Effective Approach in Photodynamic Therapy and Chemotherapy, to Overcome Multidrug Resistance in Cancer

  2022cites this paper
• A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).

  2021cites this paper
• The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy.

  2020influential citation
• Role of Bcl-2 Family Proteins in Photodynamic Therapy Mediated Cell Survival and Regulation

  2020influential citation
• Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein

  2020cites this paper
• Drug efflux pumps in photodynamic therapy

  2020cites this paper
• Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.

  2019cites this paper
• A preclinical model to investigate the role of surgically‐induced inflammation in tumor responses to intraoperative photodynamic therapy

  2018cites this paper
• Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1

  2018cites this paper
• SciFed Journal of Nuclear Science Modeling of Laser Activated Light Emitting Silica Nanorods for the Photodynmaic Therapy of Cancer

  2018cites this paper
• Glycol porphyrin derivatives and temoporfin elicit resistance to photodynamic therapy by different mechanisms

  2017cites this paper
• ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression

  2017cites this paper
• Cancer Tissue Classification, Associated Therapeutic Implications and PDT as an Alternative.

  2017cites this paper
• Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer

  2017cites this paper
• New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies

  2015cites this paper
• Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics

  2015cites this paper
• Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance.

  2015cites this paper
• Kinetic Evaluation of Determinant Factors for Cellular Accumulation of Protoporphyrin IX Induced by External 5-Aminolevulinic Acid for Photodynamic Cancer Therapy.

  2015cites this paper
• Mechanisms of Resistance to Photodynamic Therapy: An Update

  2015cites this paper
• Photodynamic therapy of cancer — Challenges of multidrug resistance

  2015cites this paper
• Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.

  2015cites this paper
• The Sensitivity of Cancer Cells to Pheophorbide a-Based Photodynamic Therapy Is Enhanced by NRF2 Silencing

  2014cites this paper
• Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.

  2014cites this paper
• Diferencias interespecíficas y polimórficas en la actividad y modulación a través de inhibidores del transportador ABCG2/BCRP = Interspecific and polymorphic differences in the activity and modulation mediated by inhibitors of the ABCG2/BCRP transporter

  2013cites this paper
• Photodynamic therapy with talaporfin sodium induces dose-dependent apoptotic cell death in human glioma cell lines.

  2013cites this paper
• Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood

  2012cites this paper
• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

  2012cites this paper
• Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

  2012cites this paper
• In Vitro Studies on Erythrosine-Based Photodynamic Therapy of Malignant and Pre-Malignant Oral Epithelial Cells

  2012cites this paper
• Molecular determinants of photodynamic therapy for lung cancers

  2011influential citation
• Transport processes of radiopharmaceuticals and -modulators

  2011influential citation
• Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells.

  2011cites this paper
• Cell‐type Selective Phototoxicity Achieved with Chlorophyll‐a Derived Photosensitizers in a Co‐culture System of Primary Human Tumor and Normal Lung Cells

  2011influential citation
• The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival.

  2011cites this paper
• Mechanisms of resistance to photodynamic therapy.

  2011cites this paper
• Cytotoxic and photocytotoxic effect of Photofrin® on human laryngeal carcinoma (Hep2c) cell line

  2011cites this paper
• Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.

  2010cites this paper
• TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy

  2010cites this paper